Gastrointestinal Research Group, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom.
Clin Gastroenterol Hepatol. 2013 Feb;11(2):109-18; quiz e13-4. doi: 10.1016/j.cgh.2012.08.037. Epub 2012 Sep 12.
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, more commonly referred to as statins, comprise a family of lipid-lowering drugs that are prescribed on a global scale on account of their proven safety and efficacy in reducing mortality from cardiovascular disease. Beyond their potent pharmacologic inhibition of cholesterol biosynthesis, statins appear to have pleiotropic effects, including modulation of cell growth, apoptosis, and inflammation. Through modulation of these pathways, statins have the potential to influence a wide range of disease processes, including cancer. Much attention has focused on the association between statins and colorectal cancer, raising the prospect that these well-tolerated compounds could form the basis of future chemopreventive strategies. Herein, we review the epidemiologic, clinical, and preclinical data relevant to statins and colorectal neoplasia, and discuss the current status and future potential of statins as chemopreventive agents.
3-羟基-3-甲基戊二酰辅酶 A 还原酶抑制剂，通常被称为他汀类药物，属于一类降脂药物，由于其在降低心血管疾病死亡率方面的安全性和有效性已得到证实，因此在全球范围内得到广泛应用。除了强效抑制胆固醇生物合成的药理学作用外，他汀类药物似乎还具有多种作用，包括调节细胞生长、凋亡和炎症。通过调节这些途径，他汀类药物有可能影响广泛的疾病过程，包括癌症。人们非常关注他汀类药物与结直肠癌之间的关联，这使得人们有理由认为这些耐受性良好的化合物可能成为未来化学预防策略的基础。本文综述了与他汀类药物和结直肠肿瘤相关的流行病学、临床和临床前数据，并讨论了他汀类药物作为化学预防剂的现状和未来潜力。
